{"filings":[{"id":94290,"accession_number":"0001193125-26-206396","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q1 loss $15.2M; cash $192M; nominates two new PI3Kα inhibitors; halting OKI-219","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.2M ($1.11 per share) for Q1 2026 vs $15.9M ($1.19 per share) in Q1 2025.","Cash and cash equivalents $192.1M as of March 31, 2026, including $150M private placement closed on March 31, expected to fund operations into 2029.","Announced nomination of OKI-355 for vascular anomalies and OKI-345 for breast cancer; IND submissions planned for first half 2027.","Company will not independently pursue further clinical development of OKI-219; data from PIKture-01 study to be reported by end of 2026.","R&D expenses $11.7M (down from $13.0M), G&A $3.9M (down from $4.0M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106530,"accession_number":"0001193125-26-130283","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"OnKure raises $150M in PIPE; plans IND filings for PI3Kα pan-mutant inhibitors in H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~26.7M shares at $4.15 and ~9.4M pre-funded warrants; gross proceeds ~$150M.","Proceeds to fund development of PI3Kα pan-mutant inhibitors OKI-345 (breast cancer) and OKI-355 (vascular anomalies).","IND submissions for OKI-345 and OKI-355 planned for H1 2027; no further independent development of OKI-219.","Dr. Liam Ratcliffe appointed to board effective at closing, designated by lead investor AI Biotechnology.","Officers/directors and company subject to 180-day lock-up (or until registration effective) on share issuance/sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106529,"accession_number":"0001193125-26-104104","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Therapeutics Q4 2025 net loss narrows to $13.5M; expects March data readouts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.5M ($0.99/sh) for Q4 2025 vs $17.4M ($1.37/sh) in Q4 2024; expenses decreased.","Cash and equivalents $59.1M as of Dec 31, 2025.","PIKture-01 trial (OKI-219) data expected March 2026 across mono, combo, and triplet arms.","Next-gen PI3Kα pan-mutant inhibitor candidate for HR+ breast cancer to be announced March 2026.","R&D expenses $10.7M vs $14.4M YoY; G&A $3.4M vs $4.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122874,"accession_number":"0001193125-25-269652","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"OnKure enters ATM offering agreement with Leerink Partners; up to 3% fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Leerink Partners for at-the-market offering of Class A common stock.","Compensation set at 3.0% of gross proceeds from sales of Placement Shares.","No minimum offering amount; company may suspend sales at any time.","Sales commence only after SEC registration statement becomes effective.","Agreement contains customary representations, warranties, and termination provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122873,"accession_number":"0001193125-25-269468","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.","Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.","First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.","Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.","Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139567,"accession_number":"0001193125-25-178978","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.","Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.","Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.","New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.","New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157146,"accession_number":"0000950170-25-090403","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"OnKure Therapeutics posts updated corporate presentation to IR website","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["OnKure posted an updated corporate presentation on June 26, 2025.","Presentation is furnished as Exhibit 99.1 to Form 8-K.","No specific financial or operational details are provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157145,"accession_number":"0000950170-25-078375","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"OnKure shareholders elect Manke and Saccomano as Class I directors, ratify KPMG as auditor for FY2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Isaac Manke elected with 4,589,481 for, 882,303 withheld; Dr. Nicholas Saccomano with 5,209,380 for, 262,404 withheld.","KPMG LLP ratified as independent auditor for fiscal year ending December 31, 2025 (6,750,408 for, 111,715 against, 208 abstain).","Both directors will serve until the 2028 annual meeting of stockholders.","Broker non-votes totaled 1,390,547 for each director proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157144,"accession_number":"0000950170-25-063969","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.","Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.","PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.","Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.","Pan-mutant PI3Kα development candidate to be announced in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175503,"accession_number":"0000950170-25-036306","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OnKure Q4 2024 net loss $17.4M; cash $110.8M; PIKture-01 data in H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 $17.4M ($1.37/share) vs $9.5M ($30.14/share) in Q4 2023; R&D expense rose $5.6M.","Cash and equivalents $110.8M; expected to fund operations into Q4 2026 through multiple clinical readouts.","PIKture-01 Part A monotherapy enrollment near complete; PK and preliminary efficacy data expected H2 2025.","Part B fulvestrant combination dosing initiated through 900 mg BID cohort; initial data due H2 2025.","Pan-mutant PI3Kα development candidate to be announced in Q2 2025; aims for ~10x selectivity over wild type."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192453,"accession_number":"0000950170-24-134757","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OKI-219 well-tolerated in first human trial; no hyperglycemia, Part 1b combo initiated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["17 patients dosed across 300–900 mg BID; no dose interruptions, reductions, or discontinuations.","Only Grade 1 TRAEs reported (diarrhea, nausea, pruritus); no hyperglycemia observed.","900 mg BID achieved steady-state PK with near-continuous EC80 coverage for pAKT inhibition.","Two HR+/HER2- breast cancer patients on 300 mg showed >7 months stable disease; one had >95% ctDNA reduction.","Part 1b evaluating OKI-219 + fulvestrant initiated; single-agent/combination data expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192452,"accession_number":"0000950170-24-123265","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Legacy OnKure posts $35.2M net loss in 9mo; auditor switched to KPMG post-merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $35.2M for nine months ended Sep 30, 2024, vs $25.9M in prior year.","Cash and equivalents $8.0M as of Sep 30, 2024; accumulated deficit $137.3M.","Ernst & Young dismissed as auditor; KPMG engaged as new independent registered public accounting firm.","Merger with Reneo closed Oct 4, 2024; management expects combined cash to fund operations for at least 12 months.","Convertible notes payable of $6.0M issued in 2024, net of $142k issuance costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192451,"accession_number":"0001193125-24-234487","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["2.01","3.02","9.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"status":"ready","headline":"OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.","PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M.","Reverse stock split 1:10, name change to OnKure Therapeutics, ticker changes from RPHM to OKUR.","Lead candidate OKI-219 (PI3Kα H1047R inhibitor) in Phase 1; early data expected Q4 2024.","New board and management: Nicholas Saccomano CEO, Samuel Agresta CMO, Jason Leverone CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192454,"accession_number":"0001193125-24-231281","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Reneo stockholders approve all proposals for OnKure merger at special meeting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Proposal 1 (stock issuance for merger) approved: 21.87M for, 110.6K against.","Proposal 2 (PIPE stock issuance >20%) approved: 21.87M for, 110.7K against.","Proposal 4 (reverse stock split) approved: 21.85M for, 131.9K against.","Proposals 5 and 6 (NewCo equity plans) approved by 17.48M and 18.38M votes for.","All seven proposals passed; adjournment not needed as quorum and votes were sufficient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208922,"accession_number":"0001193125-24-222429","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Reneo faces two shareholder lawsuits over OnKure merger proxy; provides supplemental disclosures","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two complaints filed in NY Supreme Court allege misrepresentations/omissions in proxy regarding financial projections and advisor conflicts.","Reneo denies allegations but voluntarily supplements proxy with details on Leerink's $40k prior compensation and 5% aggregate placement agent fee.","Supplemental disclosures include unadjusted OnKure forecasts showing projected net sales up to $3B by 2042 and DCF equity value range of $180M-$290M.","Reneo confirms no internal liquidation analysis was prepared; board relied on OnKure forecasts and $15M enterprise value ascribed to Reneo.","Merger and concurrent PIPE expected to close; company intends to vigorously defend against litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208921,"accession_number":"0001193125-24-218879","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.","Termination linked to planned merger with OnKure, Inc. and cessation of drug development.","Hall will receive severance benefits under previously disclosed severance plan.","Merger with OnKure is expected to shift company away from historical drug development.","Gregory J. Flesher remains CEO; no replacement for CDO announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208920,"accession_number":"0000950170-24-096127","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharma Q2 net loss $5.4M; merger with OnKure on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.4M ($0.16 per share) vs $19.5M ($0.65) in Q2 2023; cash $76.7M at June 30.","R&D expenses fell to $0.6M from $14.4M due to suspension of mavodelpar development and workforce cuts.","Merger with OnKure (all-stock) plus $65M PIPE expected to close H2 2024; combined cash ~$120M.","General and administrative expenses $5.8M vs $6.6M, with $2.4M increase in legal/advisory fees for merger."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226736,"accession_number":"0001193125-24-136785","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.","Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.","OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).","Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.","Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226735,"accession_number":"0000950170-24-054442","cik":1637715,"company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Reneo Pharmaceuticals initiates strategic alternatives review after failed trial; Q1 net loss $8.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STRIDE study of mavodelpar in primary mitochondrial myopathies missed all endpoints in Dec 2023.","Suspended all mavodelpar development; reduced workforce by ~90% in Dec 2023 and Feb 2024.","Retained independent financial advisor to explore strategic alternatives, including possible sale.","Q1 2024 net loss $8.4M ($0.25/share) vs $15.1M ($0.60/share) Q1 2023; cash $82.8M as of Mar 31, 2024.","R&D expenses fell to $4.9M from $11.0M due to program suspension and cost-cutting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":166833333.40731707,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}